US5929549A
(en)
*
|
1998-04-02 |
1999-07-27 |
Pacific Scientific Company |
Fault tolerant electric machine
|
US6437529B1
(en)
*
|
1998-05-04 |
2002-08-20 |
Comair Rotron, Inc. |
Multi-stator motor with independent stator circuits
|
DE19856647B4
(en)
*
|
1998-12-09 |
2007-03-01 |
Canders, Wolf-R., Prof. Dr.-Ing. |
Electric high-torque motor
|
EP1262687B1
(en)
*
|
2001-06-01 |
2009-03-25 |
IHI Aerospace Co., Ltd. |
Electromotive actuator and method for controlling the same
|
DE60215095T2
(en)
*
|
2001-09-19 |
2007-05-10 |
Parker-Hannifin Corp., Cleveland |
Motor drive and system
|
US6791209B2
(en)
|
2002-01-02 |
2004-09-14 |
Intel Corporation |
Power and control for power supply fans
|
US6700266B2
(en)
*
|
2002-01-02 |
2004-03-02 |
Intel Corporation |
Multiple fault redundant motor
|
US6819017B2
(en)
|
2002-01-02 |
2004-11-16 |
Intel Corporation |
Method and apparatus for fan redundancy
|
US6724183B2
(en)
|
2002-01-02 |
2004-04-20 |
Intel Corporation |
Method and apparatus for detecting bearing failure
|
US20090326042A1
(en)
|
2006-05-05 |
2009-12-31 |
Isis Pharmaceuticals, Inc |
Compounds and methods for modulating expression of crp
|
EP2505649A1
(en)
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of GCGR
|
US7443642B2
(en)
|
2006-05-26 |
2008-10-28 |
Pratt & Whitney Canada Corp. |
Electric motor control
|
GB0613941D0
(en)
*
|
2006-07-13 |
2006-08-23 |
Pml Flightlink Ltd |
Electronically controlled motors
|
EP2410053B2
(en)
|
2006-10-18 |
2020-07-15 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds
|
US7605503B2
(en)
|
2007-03-28 |
2009-10-20 |
General Electric Company |
Fault-tolerant permanent magnet machine with reconfigurable stator core slot opening and back iron flux paths
|
US7605504B2
(en)
|
2007-03-28 |
2009-10-20 |
General Electric Company |
Fault-tolerant permanent magnet machine with reconfigurable stator core slot flux paths
|
US7541705B2
(en)
|
2007-03-28 |
2009-06-02 |
General Electric Company |
Fault-tolerant permanent magnet machine with reconfigurable flux paths in stator back iron
|
DE102007048642A1
(en)
*
|
2007-10-10 |
2009-04-16 |
Mtu Aero Engines Gmbh |
Electric drive, in particular for a fuel metering unit for an aircraft engine
|
US7786684B2
(en)
*
|
2007-10-22 |
2010-08-31 |
Honeywell International Inc. |
Electromechanical flight control system and method for rotorcraft
|
EP2297322A1
(en)
|
2008-06-04 |
2011-03-23 |
The Board of Regents of The University of Texas System |
Modulation of gene expression through endogenous small rna targeting of gene promoters
|
US8901095B2
(en)
|
2008-07-29 |
2014-12-02 |
The Board Of Regents Of The University Of Texas System |
Selective inhibition of polyglutamine protein expression
|
US8987435B2
(en)
|
2008-10-24 |
2015-03-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
US8476798B2
(en)
|
2008-11-28 |
2013-07-02 |
Pratt & Whitney Canada Corp. |
Tandem electric machine arrangement
|
US20120021515A1
(en)
|
2009-02-06 |
2012-01-26 |
Swayze Eric E |
Oligomeric compounds and methods
|
EP2421972A2
(en)
|
2009-04-24 |
2012-02-29 |
The Board of Regents of The University of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
|
GB2462940B8
(en)
*
|
2009-09-03 |
2012-03-28 |
Protean Holdings Corp |
Electric motor and electric generator.
|
US8749192B2
(en)
|
2009-09-03 |
2014-06-10 |
Protean Electric Limited |
Electric motor and electric generator
|
US20110110860A1
(en)
|
2009-11-02 |
2011-05-12 |
The Board Of Regents Of The University Of Texas System |
Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
|
AU2011203986C1
(en)
|
2010-01-08 |
2015-03-05 |
Ionis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
WO2011097388A1
(en)
|
2010-02-03 |
2011-08-11 |
Alnylam Pharmaceuticals, Inc. |
Selective inhibition of polyglutamine protein expression
|
JP6018506B2
(en)
|
2010-02-08 |
2016-11-02 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
Selective reduction of allelic variants
|
US8957040B2
(en)
|
2010-02-08 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
WO2011139695A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
|
EP2601204B1
(en)
|
2010-04-28 |
2016-09-07 |
Ionis Pharmaceuticals, Inc. |
Modified nucleosides and oligomeric compounds prepared therefrom
|
EP3091027B1
(en)
|
2010-04-28 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
5' modified nucleosides and oligomeric compounds prepared therefrom
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
WO2011139917A1
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression
|
US8957200B2
(en)
|
2010-06-07 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011156202A1
(en)
|
2010-06-08 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2012012467A2
(en)
|
2010-07-19 |
2012-01-26 |
Isis Pharmaceuticals, Inc. |
Modulation of nuclear-retained rna
|
JP5577506B2
(en)
|
2010-09-14 |
2014-08-27 |
ソーラテック コーポレイション |
Centrifugal pump device
|
FR2967310B1
(en)
|
2010-11-04 |
2013-08-02 |
Xap |
ELECTROMAGNETIC MOTOR WITHOUT BRUSH
|
WO2012068405A2
(en)
|
2010-11-17 |
2012-05-24 |
Isis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
US10017764B2
(en)
|
2011-02-08 |
2018-07-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
EP2693609B1
(en)
|
2011-03-28 |
2017-05-03 |
Thoratec Corporation |
Rotation and drive device and centrifugal pump device using same
|
KR102050469B1
(en)
|
2011-04-01 |
2019-12-02 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Modulation of signal transducer and activator of transcription 3 (stat3) expression
|
DE102011016336A1
(en)
|
2011-04-07 |
2012-10-11 |
Airbus Operations Gmbh |
High-lift system for an aircraft
|
AU2012242642A1
(en)
|
2011-04-13 |
2013-05-02 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
CN111172162A
(en)
|
2011-04-21 |
2020-05-19 |
葛兰素史克公司 |
Modulation of Hepatitis B Virus (HBV) expression
|
RU2603076C9
(en)
|
2011-04-27 |
2017-02-03 |
Айсис Фармасьютикалс, Инк. |
MODULATION OF APOLIPOPROTEIN CIII (ApoCIII) EXPRESSION
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2717923B1
(en)
|
2011-06-10 |
2017-09-27 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (klkb1) expression
|
CN103597074A
(en)
|
2011-06-16 |
2014-02-19 |
Isis制药公司 |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
CA2840614A1
(en)
|
2011-06-29 |
2013-01-03 |
Isis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (klkb1) expression
|
US10202599B2
(en)
|
2011-08-11 |
2019-02-12 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
US10023861B2
(en)
|
2011-08-29 |
2018-07-17 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
CN103814132B
(en)
|
2011-09-20 |
2018-06-05 |
苏州瑞博生物技术有限公司 |
The antisense of GCGR expression is adjusted
|
CN103906838A
(en)
|
2011-10-25 |
2014-07-02 |
Isis制药公司 |
Antisense modulation of GCCR expression
|
US9725722B2
(en)
|
2011-11-07 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
Modulation of TMPRSS6 expression
|
AU2012358238B2
(en)
|
2011-12-22 |
2017-12-07 |
C. Frank Bennett |
Methods for modulating Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1(MALAT-1) expression
|
ES2842938T3
(en)
|
2012-01-11 |
2021-07-15 |
Ionis Pharmaceuticals Inc |
Compositions and Methods for IKBKAP Splice Modulation
|
EP2812342B1
(en)
|
2012-02-08 |
2017-11-15 |
Ionis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
US8837096B2
(en)
|
2012-03-13 |
2014-09-16 |
Thoratec Corporation |
Fault monitor for fault tolerant implantable pump
|
EP2850092B1
(en)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2013159108A2
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
US9518261B2
(en)
|
2012-05-22 |
2016-12-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of enhancer RNA mediated gene expression
|
KR20190084354A
(en)
|
2012-05-24 |
2019-07-16 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Methods and compositions for modulating apolipoprotein (a) expression
|
ES2688831T3
(en)
|
2012-06-25 |
2018-11-07 |
Ionis Pharmaceuticals, Inc. |
UBE3A-ATS expression modulation
|
EP3693460A1
(en)
|
2012-07-27 |
2020-08-12 |
Ionis Pharmaceuticals, Inc. |
Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
|
US9993522B2
(en)
|
2012-09-18 |
2018-06-12 |
Uti Limited Partnership |
Treatment of pain by inhibition of USP5 de-ubiquitinase
|
EP4052709A1
(en)
|
2012-10-11 |
2022-09-07 |
Ionis Pharmaceuticals, Inc. |
Methods of treating kennedy's disease
|
US9175291B2
(en)
|
2012-10-11 |
2015-11-03 |
Isis Pharmaceuticals Inc. |
Modulation of androgen receptor expression
|
US20150275208A1
(en)
|
2012-10-12 |
2015-10-01 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
EP2906255B1
(en)
|
2012-10-12 |
2023-02-22 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
WO2014062686A1
(en)
|
2012-10-15 |
2014-04-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating c9orf72 expression
|
HUE041632T2
(en)
|
2012-10-31 |
2019-05-28 |
Ionis Pharmaceuticals Inc |
Cancer treatment
|
US20150291958A1
(en)
|
2012-11-15 |
2015-10-15 |
Roche Innovation Center Copenhagen A/S |
Anti apob antisense conjugate compounds
|
KR20150088305A
(en)
|
2012-11-26 |
2015-07-31 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
Compositions and methods for modulation of fgfr3 expression
|
US8968174B2
(en)
|
2013-01-16 |
2015-03-03 |
Thoratec Corporation |
Motor fault monitor for implantable blood pump
|
US9371826B2
(en)
|
2013-01-24 |
2016-06-21 |
Thoratec Corporation |
Impeller position compensation using field oriented control
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
RU2018108405A
(en)
|
2013-01-30 |
2019-02-26 |
Ф. Хоффманн-Ля Рош Аг |
CARBOHYDRATE AND LNA-OLIGONUCLEOTIDE CONJUGATES
|
WO2014121287A2
(en)
|
2013-02-04 |
2014-08-07 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
AU2014216137B2
(en)
|
2013-02-14 |
2018-05-10 |
Ionis Pharmaceuticals, Inc. |
Modulation of Apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
|
US9556873B2
(en)
|
2013-02-27 |
2017-01-31 |
Tc1 Llc |
Startup sequence for centrifugal pump with levitated impeller
|
EP2961853B1
(en)
|
2013-02-28 |
2018-09-19 |
The Board of Regents of The University of Texas System |
Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
|
DE102013102194A1
(en)
*
|
2013-03-06 |
2014-09-11 |
Werner Eck |
Drive device for a moving in a fluid vehicle
|
BR112015022156A2
(en)
|
2013-03-14 |
2017-11-14 |
Isis Pharmaceuticals Inc |
compositions and methods for modulating tau expression
|
US10052420B2
(en)
|
2013-04-30 |
2018-08-21 |
Tc1 Llc |
Heart beat identification and pump speed synchronization
|
AU2014259759B2
(en)
|
2013-05-01 |
2020-06-18 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods
|
WO2014205451A2
(en)
|
2013-06-21 |
2014-12-24 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
WO2014205449A2
(en)
|
2013-06-21 |
2014-12-24 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
|
EP3591054A1
(en)
|
2013-06-27 |
2020-01-08 |
Roche Innovation Center Copenhagen A/S |
Antisense oligomers and conjugates targeting pcsk9
|
RU2700244C2
(en)
|
2013-07-02 |
2019-09-13 |
Ионис Фармасьютикалз, Инк. |
Modulators of growth hormone receptor
|
TWI657819B
(en)
|
2013-07-19 |
2019-05-01 |
美商Ionis製藥公司 |
Compositions for modulating tau expression
|
AU2014306271A1
(en)
|
2013-08-08 |
2016-03-24 |
The Scripps Research Institute |
A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
|
TW201536329A
(en)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
|
JP6652922B2
(en)
|
2013-08-28 |
2020-02-26 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
Regulation of prekallikrein (PKK) expression
|
PE20190354A1
(en)
|
2013-09-13 |
2019-03-07 |
Ionis Pharmaceuticals Inc |
COMPLEMENT B FACTOR MODULATORS
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
SG11201602597YA
(en)
|
2013-10-11 |
2016-05-30 |
Ionis Pharmaceuticals Inc |
Compositions for modulating c9orf72 expression
|
US9239345B2
(en)
|
2013-11-20 |
2016-01-19 |
Woodward, Inc. |
Controlling a motor with two or more Hall sensors
|
DK3077510T3
(en)
|
2013-12-02 |
2020-06-08 |
Ionis Pharmaceuticals Inc |
ANTISENSE COMPOUNDS AND APPLICATIONS THEREOF
|
AU2014369900B2
(en)
|
2013-12-24 |
2021-05-20 |
Ionis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
US10988030B2
(en)
|
2014-09-26 |
2021-04-27 |
Francis Xavier Gentile |
Electric motor, generator and battery combination
|
DK3119888T3
(en)
|
2014-03-19 |
2021-09-06 |
Ionis Pharmaceuticals Inc |
COMPOSITIONS FOR MODULATING ATAXIN-2 EXPRESSION
|
EP3757214B1
(en)
|
2014-04-01 |
2022-06-15 |
Biogen MA Inc. |
Compositions for modulating sod-1 expression
|
DK3129493T3
(en)
|
2014-04-09 |
2021-09-27 |
Scripps Research Inst |
Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
|
WO2015164693A1
(en)
|
2014-04-24 |
2015-10-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
WO2015168172A1
(en)
|
2014-04-28 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
WO2015168514A1
(en)
|
2014-05-01 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
MX2016014140A
(en)
|
2014-05-01 |
2017-09-15 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating pkk expression.
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
US9623161B2
(en)
|
2014-08-26 |
2017-04-18 |
Tc1 Llc |
Blood pump and method of suction detection
|
WO2016077704A1
(en)
|
2014-11-14 |
2016-05-19 |
The Regents Of The University Of California |
Modulation of agpat5 expression
|
CN105634225B
(en)
*
|
2014-11-26 |
2020-10-09 |
德昌电机(深圳)有限公司 |
Brushless DC motor and electric power steering system using the same
|
EP3229842B1
(en)
|
2014-12-08 |
2022-07-06 |
The Board of Regents of The University of Texas System |
Lipocationic polymers and uses thereof
|
US20170369872A1
(en)
|
2014-12-18 |
2017-12-28 |
Alnylam Pharmaceuticals, Inc. |
Reversir tm compounds
|
CN104617827B
(en)
*
|
2015-02-02 |
2017-05-31 |
东南大学 |
A kind of axial magnetic field flux switch permanent magnet motor fault tolerant control method used for electric vehicle
|
EP3256183A4
(en)
|
2015-02-11 |
2018-09-19 |
Tc1 Llc |
Heart beat identification and pump speed synchronization
|
US10166318B2
(en)
|
2015-02-12 |
2019-01-01 |
Tc1 Llc |
System and method for controlling the position of a levitated rotor
|
US10371152B2
(en)
|
2015-02-12 |
2019-08-06 |
Tc1 Llc |
Alternating pump gaps
|
US10245361B2
(en)
|
2015-02-13 |
2019-04-02 |
Tc1 Llc |
Impeller suspension mechanism for heart pump
|
AU2016222546B2
(en)
|
2015-02-26 |
2020-01-23 |
Ionis Pharmaceuticals, Inc. |
Allele specific modulators of P23H rhodopsin
|
ES2909308T3
(en)
|
2015-03-03 |
2022-05-06 |
Ionis Pharmaceuticals Inc |
Methods for modulating MECP2 expression
|
EP3265098A4
(en)
|
2015-03-03 |
2019-02-13 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating mecp2 expression
|
JP2018519811A
(en)
|
2015-06-29 |
2018-07-26 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
WO2017011276A1
(en)
|
2015-07-10 |
2017-01-19 |
Ionis Pharmaceuticals, Inc. |
Modulators of diacyglycerol acyltransferase 2 (dgat2)
|
US11053495B2
(en)
|
2015-07-17 |
2021-07-06 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
KR20240027890A
(en)
|
2015-09-14 |
2024-03-04 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Lipocationic dendrimers and uses thereof
|
EP3353328A4
(en)
|
2015-09-24 |
2019-06-12 |
Ionis Pharmaceuticals, Inc. |
Modulators of kras expression
|
US10117983B2
(en)
|
2015-11-16 |
2018-11-06 |
Tc1 Llc |
Pressure/flow characteristic modification of a centrifugal pump in a ventricular assist device
|
US11761007B2
(en)
|
2015-12-18 |
2023-09-19 |
The Scripps Research Institute |
Production of unnatural nucleotides using a CRISPR/Cas9 system
|
CA3024129A1
(en)
|
2016-05-16 |
2017-11-23 |
The Board Of Regents Of The University Of Texas System |
Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
|
ES2929047T3
(en)
|
2016-06-24 |
2022-11-24 |
Scripps Research Inst |
Novel nucleoside triphosphate transporter and uses thereof
|
US11148819B2
(en)
|
2019-01-23 |
2021-10-19 |
H55 Sa |
Battery module for electrically-driven aircraft
|
US11065979B1
(en)
|
2017-04-05 |
2021-07-20 |
H55 Sa |
Aircraft monitoring system and method for electric or hybrid aircrafts
|
US11063323B2
(en)
|
2019-01-23 |
2021-07-13 |
H55 Sa |
Battery module for electrically-driven aircraft
|
US10854866B2
(en)
|
2019-04-08 |
2020-12-01 |
H55 Sa |
Power supply storage and fire management in electrically-driven aircraft
|
US10322824B1
(en)
|
2018-01-25 |
2019-06-18 |
H55 Sa |
Construction and operation of electric or hybrid aircraft
|
US10807729B2
(en)
*
|
2017-05-17 |
2020-10-20 |
General Electric Company |
Propulsion system for an aircraft
|
NZ761430A
(en)
|
2017-08-03 |
2024-03-22 |
Synthorx Inc |
Cytokine conjugates for the treatment of proliferative and infectious diseases
|
JP2021514974A
(en)
|
2018-02-26 |
2021-06-17 |
シンソークス, インコーポレイテッド |
IL-15 conjugate and its use
|
JP7353301B2
(en)
|
2018-05-07 |
2023-09-29 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
Extrahepatic delivery
|
EP3856907A1
(en)
|
2018-09-28 |
2021-08-04 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
BR112021014415A2
(en)
|
2019-02-06 |
2021-09-21 |
Synthorx, Inc. |
IL-2 CONJUGATES AND METHODS OF USING THEM
|
CA3198063A1
(en)
|
2019-03-29 |
2020-10-08 |
Mitsubishi Tanabe Pharma Corporation |
Compound, method and pharmaceutical composition for modulating expression of dux4
|
US20220211743A1
(en)
|
2019-05-17 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
MX2022001776A
(en)
|
2019-08-15 |
2022-03-17 |
Synthorx Inc |
Immuno oncology combination therapies with il-2 conjugates.
|
MX2022002053A
(en)
|
2019-08-23 |
2022-03-17 |
Synthorx Inc |
Il-15 conjugates and uses thereof.
|
US20210070827A1
(en)
|
2019-09-10 |
2021-03-11 |
Synthorx, Inc. |
Il-2 conjugates and methods of use to treat autoimmune diseases
|
TW202131952A
(en)
|
2019-11-04 |
2021-09-01 |
美商欣爍克斯公司 |
Interleukin 10 conjugates and uses thereof
|
EP4055165A1
(en)
|
2019-11-06 |
2022-09-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
MX2022005220A
(en)
|
2019-11-06 |
2022-08-11 |
Alnylam Pharmaceuticals Inc |
Extrahepatic delivery.
|
US20230227824A1
(en)
|
2020-05-12 |
2023-07-20 |
Mitsubishi Tanabe Pharma Corporation |
Compound, method and pharmaceutical composition for regulating expression of ataxin 3
|
KR20230027235A
(en)
|
2020-06-25 |
2023-02-27 |
신톡스, 인크. |
Immuno-oncology combination therapy using IL-2 conjugates and anti-EGFR antibodies
|
US20230257745A1
(en)
|
2020-07-10 |
2023-08-17 |
Alnylam Pharmaceuticals, Inc. |
Circular siRNAs
|
MX2023004029A
(en)
|
2020-10-09 |
2023-04-27 |
Synthorx Inc |
Immuno oncology combination therapy with il-2 conjugates and pembrolizumab.
|
AU2021356610A1
(en)
|
2020-10-09 |
2023-06-15 |
Synthorx, Inc. |
Immuno oncology therapies with il-2 conjugates
|
KR20230136130A
(en)
|
2020-12-31 |
2023-09-26 |
알닐람 파마슈티칼스 인코포레이티드 |
Cyclic-disulfide modified phosphate-based oligonucleotide prodrug
|
EP4271695A2
(en)
|
2020-12-31 |
2023-11-08 |
Alnylam Pharmaceuticals, Inc. |
2'-modified nucleoside based oligonucleotide prodrugs
|
WO2022174101A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Skin cancer combination therapy with il-2 conjugates and cemiplimab
|
WO2022174102A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
|
EP4314016A1
(en)
|
2021-03-31 |
2024-02-07 |
Entrada Therapeutics, Inc. |
Cyclic cell penetrating peptides
|
AU2022271873A1
(en)
|
2021-05-10 |
2024-01-04 |
Entrada Therapeutics, Inc. |
Compositions and methods for intracellular therapeutics
|
WO2022240721A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
|
EP4337261A2
(en)
|
2021-05-10 |
2024-03-20 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating mrna splicing
|
US11682997B2
(en)
|
2021-05-17 |
2023-06-20 |
Hitachi Astemo Americas, Inc. |
Rotary electric machine with selectable coil control
|
WO2022256538A1
(en)
|
2021-06-03 |
2022-12-08 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
|
WO2022271818A1
(en)
|
2021-06-23 |
2022-12-29 |
Entrada Therapeutics, Inc. |
Antisense compounds and methods for targeting cug repeats
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
KR20240036041A
(en)
|
2021-07-21 |
2024-03-19 |
알닐람 파마슈티칼스 인코포레이티드 |
Metabolic Disorder-Associated Target Gene iRNA Composition and Methods of Using Same
|
WO2023034817A1
(en)
|
2021-09-01 |
2023-03-09 |
Entrada Therapeutics, Inc. |
Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
|
WO2023064530A1
(en)
|
2021-10-15 |
2023-04-20 |
Alnylam Pharmaceuticals, Inc. |
Extra-hepatic delivery irna compositions and methods of use thereof
|
WO2023086292A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
WO2023086295A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Antisense oligonucleotides for modifying protein expression
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
WO2023220744A2
(en)
|
2022-05-13 |
2023-11-16 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
WO2024006999A2
(en)
|
2022-06-30 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024050261A1
(en)
|
2022-08-29 |
2024-03-07 |
University Of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
WO2024073732A1
(en)
|
2022-09-30 |
2024-04-04 |
Alnylam Pharmaceuticals, Inc. |
Modified double-stranded rna agents
|